The Misanthrope Quiz | Eight Week Quiz A

This set of Lesson Plans consists of approximately 275 pages of tests, essay questions, lessons, and other teaching materials.

The Misanthrope Quiz | Eight Week Quiz A

This set of Lesson Plans consists of approximately 275 pages of tests, essay questions, lessons, and other teaching materials.
Buy The Misanthrope Lesson Plans
Name: _________________________ Period: ___________________

This quiz consists of 5 multiple choice and 5 short answer questions through Act 2, Scene 1.

Multiple Choice Questions

1. How does Oronte chastise his subject in the sonnet?
(a) He refuses to read the sonnet.
(b) He discusses his love lost.
(c) His subject belittles him.
(d) His subject gives him false hope.

2. Who is Alceste jealous of?
(a) Orotne.
(b) Celimene.
(c) Philinte.
(d) Clitandre.

3. What does Alceste think about Philinte response to the sonnet?
(a) He understands Philinte.
(b) He scolds Philinte.
(c) He praises Philinte.
(d) He is confused by the response.

4. While Oronte is reading his sonnet, what does Alceste whisper to Philinte?
(a) Alceste tells Philinte that they should applaud when the poem is over.
(b) Alceste asks if the sonnet is almost over.
(c) Alceste criticizes what Oronte is wearing.
(d) Alceste criticizes Philinte's praising of the sonnet.

5. What does Celimene threaten to do if Alceste continues being suspicious of her?
(a) To marry Philinte instead.
(b) To retract her declaration of love.
(c) To stop being Alceste's friend.
(d) To never speak to Alceste again.

Short Answer Questions

1. What medical problem is Alceste suspected on having?

2. What does Alceste tell Philinte as he leaves?

3. What does Alceste wish he can do about Celimene?

4. During the heated discussion, what does Alceste reveal is aggravating him?

5. What is Alceste response to the sonnet?

(see the answer key)

This section contains 251 words
(approx. 1 page at 300 words per page)
Buy The Misanthrope Lesson Plans
Copyrights
BookRags
The Misanthrope from BookRags. (c)2024 BookRags, Inc. All rights reserved.